Amide Bioisostere Replacement: Pyridazine Carboxamide Scaffold
Structural Rigidity and Metabolic Stability of 6-Oxo-1,6-dihydro-3-pyridazinecarboxamide as a Benzamide Bioisostere
In the pursuit of optimizing pharmacokinetic profiles, medicinal chemists frequently turn to amide bioisostere replacement strategies. The pyridazine carboxamide scaffold, specifically 6-oxo-1,6-dihydro-3-pyridazinecarboxamide (CAS 60184-73-8), offers a compelling alternative to traditional benzamide moieties. This heterocyclic core introduces conformational constraint, reducing the entropic penalty upon target binding while modulating electronic properties. The presence of the 6-oxo group and the endocyclic nitrogen atoms alters hydrogen-bonding capacity and dipole moment, which can enhance target engagement and selectivity. Unlike flexible amide chains, this rigid scaffold can improve metabolic stability by shielding the amide bond from hydrolytic enzymes. In our experience, clients transitioning from benzamide-based leads to this pyridazine derivative often observe a favorable shift in logP, typically a decrease of 0.5–1.0 units, enhancing aqueous solubility without compromising permeability. This is particularly relevant for CNS-targeted programs where balancing lipophilicity is critical. For a deeper dive into coupling strategies, see our article on sourcing pyridazine carboxamide for NLRP3 inhibitor yields.
Crystallization Process Control: Ethanol/Water Anti-Solvent Ratios and Particle Size Distribution for Kilogram-Scale Isolation
Scaling up the synthesis of 6-oxo-1,6-dihydro-3-pyridazinecarboxamide from bench to kilogram quantities demands rigorous control over crystallization parameters. At NINGBO INNO PHARMCHEM, we employ a refined ethanol/water anti-solvent crystallization protocol that ensures consistent particle size distribution (PSD) and polymorphic purity. The typical procedure involves dissolving the crude product in a minimal volume of hot ethanol, followed by controlled addition of water as the anti-solvent. The ratio of ethanol to water, cooling rate, and seeding strategy are critical. A common pitfall is the formation of fine needles that lead to poor filtration and low bulk density. Through iterative optimization, we have identified a sweet spot: a 1:3 (v/v) ethanol-to-water ratio with linear cooling from 60°C to 5°C over 4 hours, yielding dense, prismatic crystals with a D50 of 150–250 µm. This PSD is ideal for downstream formulation, ensuring good flowability and compressibility. One non-standard parameter we monitor is the solution's viscosity during the anti-solvent addition phase. At sub-ambient temperatures (below 10°C), the mixture can exhibit a transient viscosity increase, which, if not managed with adequate agitation, leads to localized supersaturation and amorphous content. Our production team mitigates this by maintaining a minimum stirring speed of 200 RPM and using a subsurface addition port for water. For Japanese-speaking clients, we have detailed this process in our article on ピリダジンカルボキサミドの調達：Nlrp3阻害剤の収率.
Purity Grades, COA Parameters, and Trace Impurity Profiles for Pharmaceutical Development
Pharmaceutical intermediates demand stringent purity specifications. Our 6-oxo-1,6-dihydro-3-pyridazinecarboxamide is routinely manufactured to a purity of ≥98% by HPLC, with a typical lot achieving 99.5% (please refer to the batch-specific COA). The primary impurity is the des-chloro analog (6-oxo-1,6-dihydro-3-pyridazinecarboxylic acid), which is controlled to <0.5%. Trace levels of the starting material, 3,6-dichloropyridazine, are monitored by GC-MS and kept below 0.1%. For clients developing APIs, we also provide a polymorph confirmation by XRPD upon request. The table below summarizes the typical COA parameters for our standard and high-purity grades.
| Parameter | Standard Grade | High Purity Grade |
|---|---|---|
| Assay (HPLC, area%) | ≥98.0% | ≥99.0% |
| Water Content (KF) | ≤0.5% | ≤0.2% |
| Residue on Ignition | ≤0.1% | ≤0.05% |
| Heavy Metals (as Pb) | ≤10 ppm | ≤5 ppm |
| Single Impurity (HPLC) | ≤1.0% | ≤0.5% |
| Appearance | White to off-white powder | White crystalline powder |
It is important to note that trace impurities can impact color. For instance, even ppm levels of iron can impart a slight yellow tint. Our process uses glass-lined reactors and purified water to minimize such contamination. For sensitive applications, we recommend the high-purity grade, which undergoes an additional recrystallization step.
Bulk Packaging and Supply Chain Reliability for Industrial Procurement
For industrial procurement, packaging integrity and supply chain resilience are paramount. NINGBO INNO PHARMCHEM offers 6-oxo-1,6-dihydro-3-pyridazinecarboxamide in standard packaging configurations: 25 kg fiber drums with double LDPE liners for solid orders, and 210L steel drums for larger quantities. For bulk shipments, we can accommodate 500 kg supersacks or IBC totes upon request. All packaging is UN-approved and suitable for air, sea, and road transport. We maintain a safety stock of 500 kg at our Ningbo warehouse, enabling lead times of 2–3 weeks for most orders. Our dual-source strategy for key raw materials, such as 3,6-dichloropyridazine, ensures uninterrupted production even during market fluctuations. As a drop-in replacement for other pyridazine carboxamide suppliers, our product matches the technical specifications of leading brands while offering a cost advantage of 15–20% due to our integrated manufacturing process. We do not claim EU REACH compliance, but our packaging meets international standards for physical containment.
Frequently Asked Questions
How does the logP of 6-oxo-1,6-dihydro-3-pyridazinecarboxamide compare to a typical benzamide?
The calculated logP of this pyridazine carboxamide is approximately -0.5, while a simple benzamide has a logP around 0.6. This reduction in lipophilicity can improve aqueous solubility and reduce off-target binding, but may require formulation adjustments for oral absorption.
What metabolic clearance rates have been observed in CYP450 assays?
In human liver microsome assays, the intrinsic clearance of 6-oxo-1,6-dihydro-3-pyridazinecarboxamide is typically low (<10 µL/min/mg), indicating good metabolic stability. The primary metabolic pathway is oxidation of the pyridazine ring, mediated by CYP3A4. However, batch-specific data should be confirmed with your DMPK team.
Is the polymorph consistent from batch to batch?
Yes, our controlled crystallization process yields the thermodynamically stable Form I polymorph consistently. We verify polymorph identity by XRPD for each batch. No form changes have been observed under accelerated stability conditions (40°C/75% RH for 6 months).
Can this compound be used as a direct replacement for a benzamide in an existing synthesis route?
In many cases, yes. The carboxylic acid or acid chloride of this pyridazine can be coupled using standard amide bond-forming reactions (e.g., HATU, EDCI). However, the electron-deficient nature of the pyridazine ring may require slightly longer reaction times or higher equivalents of coupling reagent. We recommend a small-scale feasibility study.
What is the solubility profile in common organic solvents?
6-Oxo-1,6-dihydro-3-pyridazinecarboxamide is sparingly soluble in most organic solvents. It dissolves in DMSO (≥50 mg/mL) and DMF (≥30 mg/mL) with heating. It is practically insoluble in dichloromethane, ethyl acetate, and hexane. For recrystallization, ethanol/water mixtures are optimal.
Sourcing and Technical Support
As a dedicated manufacturer of heterocyclic intermediates, NINGBO INNO PHARMCHEM provides comprehensive technical support to streamline your development process. From gram-scale samples for feasibility studies to multi-kilogram production campaigns, we ensure quality and consistency. Our team can assist with impurity identification, polymorph screening, and custom packaging solutions. To request a batch-specific COA, SDS, or secure a bulk pricing quote, please contact our technical sales team.